In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback